Business

November 8, 2013 5:09 PM

Investors applaud Salix acquisition

Wall Street gave a huge thumbs-up to Salix Pharmaceuticals’ plan to acquire specialty drug company Santarus for $2.6 billion.

Related content

Suggested for you

Comments

Videos

Today's Market

Nasdaq
Powered by Barchart

Editor's Choice Videos

Search Jobs

Enter Keyword(s)

Enter a City

Enter a State